![Fast detection of tumor marker CA 19-9 using AlGaN/GaN high electron mobility transistors - ScienceDirect Fast detection of tumor marker CA 19-9 using AlGaN/GaN high electron mobility transistors - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0925400518306968-gr1.jpg)
Fast detection of tumor marker CA 19-9 using AlGaN/GaN high electron mobility transistors - ScienceDirect
![Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function | Nature Immunology Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function | Nature Immunology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41590-023-01448-7/MediaObjects/41590_2023_1448_Fig1_HTML.png)
Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function | Nature Immunology
![Highly Sensitive Plasmonic Detection of the Pancreatic Cancer Biomarker CA 19-9 | Scientific Reports Highly Sensitive Plasmonic Detection of the Pancreatic Cancer Biomarker CA 19-9 | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-017-14688-z/MediaObjects/41598_2017_14688_Fig1_HTML.jpg)
Highly Sensitive Plasmonic Detection of the Pancreatic Cancer Biomarker CA 19-9 | Scientific Reports
![Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Oncology Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/c9fbc5a9-c2cc-43f3-a306-911f448b5f81/gr2_lrg.jpg)
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Oncology
![CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial | Journal of Clinical Oncology CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2017/jco.2017.35.issue-29/jco.2017.72.6463/20170921/images/large/jco.2017.72.6463t1.jpeg)
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial | Journal of Clinical Oncology
![CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial | Journal of Clinical Oncology CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2017/jco.2017.35.issue-29/jco.2017.72.6463/20170921/images/large/jco.2017.72.6463t2.jpeg)
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial | Journal of Clinical Oncology
![Cancers | Free Full-Text | Clinical Evaluation of CA72-4 for Screening Gastric Cancer in a Healthy Population: A Multicenter Retrospective Study Cancers | Free Full-Text | Clinical Evaluation of CA72-4 for Screening Gastric Cancer in a Healthy Population: A Multicenter Retrospective Study](https://www.mdpi.com/cancers/cancers-11-00733/article_deploy/html/images/cancers-11-00733-g001-550.jpg)
Cancers | Free Full-Text | Clinical Evaluation of CA72-4 for Screening Gastric Cancer in a Healthy Population: A Multicenter Retrospective Study
![Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs](https://www.unilabs.sk/media/2021/12/1/5/matysova-tab-1.jpg)